Who the ChondroFiller hip injection is for

The ChondroFiller hip injection suits patients with focal, full-thickness cartilage damage — Grade III or IV on the standard clinical grading scale — where the surrounding cartilage retains a healthy border and the joint itself is worth preserving. It is not designed for end-stage hip arthritis where the joint architecture has already collapsed; those patients are more likely candidates for hip resurfacing or replacement. The distinction matters because ChondroFiller works as a regenerative scaffold rather than a joint substitute, and the scaffold performs best when there is viable tissue around the defect to recruit from.

Before any appointment is arranged, a recent MRI scan of the hip is required. Imaging determines both whether a focal defect is present and how many units of ChondroFiller will be needed; any clinic quoting a price without first reviewing an MRI scan is missing a fundamental clinical step.

At Lincolnshire Hip, an online suitability assessment is available before a formal consultation with Professor Paul Lee in Grantham or Sleaford. It evaluates the hip across four dimensions — the physics of the joint (load and geometry), its biochemical environment, the biological potential for repair, and the timing of intervention relative to the progression of damage — giving patients a structured sense of where they stand before committing to an appointment.

ChondroFiller is not available on the NHS and is not covered by Bupa or AXA. The cost at Lincolnshire Hip is £2,995 per injection; the product is imported individually for each patient from Meidrix Biomedicals GmbH in Germany.

How to prepare on the morning of your appointment

A few straightforward steps on the morning will help the appointment run smoothly.

• Arrange a lift home. Local anaesthetic around the hip can cause temporary numbness or weakness in the leg, making it unsafe to drive immediately after.
• Wear loose clothing that allows easy access to the hip — loose trousers or a wrap skirt work well. You are unlikely to need to fully undress.
• Declare blood-thinning medications. This includes prescribed anticoagulants and over-the-counter aspirin. Your clinical team will have asked about these during pre-procedure consultation, but it is worth confirming if anything has changed.
• Eat a light meal beforehand. There is no requirement to fast unless mild sedation has been specifically planned for your procedure.
• Confirm your MRI has been received. The injection cannot proceed without prior defect mapping from imaging, so check with the clinic that your scan is on file before you travel.

The appointment itself is outpatient, and same-day discharge is the norm.

Why ultrasound guidance is essential for hip injections

Unlike the knee, which lies just beneath the skin, the hip joint sits several centimetres beneath layers of muscle, fat, and connective tissue on the lateral side of the pelvis. That depth creates a genuine clinical problem: a needle placed without imaging has no reliable way to confirm it has entered the joint cavity — let alone reached the precise floor of a focal cartilage defect.

Published orthobiologics data suggest that up to 30% of intra-articular injections placed without imaging guidance fail to deposit material at the intended intralesional target. For a viscosupplement or corticosteroid, imprecise placement reduces efficacy but does not negate the entire rationale. For ChondroFiller, the consequences are different: the scaffold must sit within the defect itself to do anything useful. Depositing it elsewhere in the joint cavity means it gels in the wrong location and the treatment is effectively wasted.

Real-time ultrasound changes this picture substantially. In a reported cohort of 273 hip injections performed under ultrasound guidance, accurate intra-articular placement was confirmed in 271 cases — a 99.3% success rate, with contrast distribution graded as excellent or good in over 97% of those hips. The clinician can also watch the collagen being released in real time and confirm the needle position is correct before committing to delivery, which is not possible with a landmark-guided approach.

What happens during the injection itself

The appointment takes place in a treatment room, not an operating theatre, and runs as a single outpatient visit — no general anaesthetic, no incision, and no overnight admission.

Once you are positioned comfortably — typically lying on your back or side — the clinical team will first administer a local anaesthetic to numb the skin over the hip. Preventative intravenous antibiotics are given at this stage, before the needle is introduced, as a routine infection precaution.

Ultrasound gel is then applied to the hip area, and the clinician places the probe against the skin. On a screen beside the couch, the femoral neck and the surrounding joint space come into view in real time. This live image guides every subsequent step: the clinician adjusts the needle angle continuously, watching the tip travel through the tissue layers until it reaches the precise site of the cartilage defect — not simply the joint cavity, but the focal lesion identified during your pre-procedure MRI review.

With the needle correctly positioned, the liquid ChondroFiller scaffold is slowly deposited into the defect. Over approximately three to five minutes, the collagen sets in place and begins to recruit the body's own repair cells from the surrounding tissue into the lesion — converting from a fluid into a structured, stable matrix without any prior surgical preparation of the cartilage surface. The process is confirmed on the live ultrasound image. Once delivery is complete, the needle is carefully withdrawn, pressure is applied to the entry point, and a small sterile dressing is placed over the skin.

Recovery on the day and the six weeks that follow

Once the small sterile dressing is in place and the needle has been withdrawn, the clinical part of the appointment is done. For the rest of that day, rest is the sensible default: avoid driving, hot baths, and any strenuous activity. Some tenderness or mild swelling at the injection site is normal and usually settles within 24–48 hours; ice packs applied for 15 minutes at a time can help. Keep the dressing clean and dry during that initial period. NSAIDs may be recommended for up to seven days to manage discomfort and reduce the risk of post-procedure inflammation.

The six weeks that follow

The most important aftercare instruction specific to ChondroFiller — and quite different from what follows a corticosteroid injection — is to limit weight-bearing on the treated hip for approximately six weeks. A corticosteroid injection carries no such restriction; you can typically walk normally the same day. ChondroFiller needs that window because the collagen scaffold must integrate stably into the cartilage defect before it can bear load. Returning to full activity too soon risks disrupting the matrix before it has recruited the body's own repair cells into the lesion.

This is a loading restriction, not bed rest. Gentle movement is fine and encouraged; structured physiotherapy begins during this period and is an integral part of the treatment pathway rather than an optional extra. Progress is reviewed at your six-week follow-up appointment, where the clinical team assess integration and agree the next phase of rehabilitation.

What the evidence says about how long it works

The most practical question for anyone weighing this procedure is how long the benefit is likely to last. Published clinical experience suggests symptom relief of three to five years — longer than the scaffold itself, which biodegrades and is absorbed within one to two years. The reason is mechanistic: ChondroFiller's role is not to persist as an inert filler but to recruit the body's own progenitor cells into the defect site. Once those cells have populated the matrix and begun producing repair tissue, the scaffold has done its work.

Laboratory evidence supports this mechanism directly. A 2025 ex vivo osteochondral model recorded a 2.4-fold increase in DNA content at day 14 in ChondroFiller-treated defects compared with untreated controls — a measured signal of host-cell recruitment rather than an assumed effect. Published hip cohort data additionally report approximately 30 points of improvement in the modified Harris Hip Score (mHHS), a validated patient-reported outcome measure for hip pain and function.

Where the evidence is thinner deserves a plain statement: large randomised trial data comparing the ultrasound-guided injection route with arthroscopic delivery in the hip has not yet been published, and long-term follow-up from the injection pathway remains largely observational. That reflects how recently this delivery route entered clinical use. Over 19,000 global cases have been treated to date, with a reported complaint rate of approximately 0.06% — figures that provide reasonable confidence in the safety profile while longer follow-up data accumulates.

For patients asking whether that evidence applies to their own hip, a suitability assessment with Professor Paul Lee at Lincolnshire Hip's Grantham or Sleaford clinics is the natural next step — Lincolnshire Hip accepts patients without referral.